Compare MTLS & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTLS | SPRY |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.6M | 473.4M |
| IPO Year | 2014 | 2020 |
| Metric | MTLS | SPRY |
|---|---|---|
| Price | $7.84 | $4.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 162.4K | ★ 1.3M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $84,278,000.00 |
| Revenue This Year | $6.38 | $87.40 |
| Revenue Next Year | $6.45 | $81.64 |
| P/E Ratio | $61.39 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.78 | $4.07 |
| 52 Week High | $7.97 | $13.15 |
| Indicator | MTLS | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 68.80 | 36.03 |
| Support Level | $6.37 | N/A |
| Resistance Level | N/A | $8.61 |
| Average True Range (ATR) | 0.23 | 0.25 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 84.54 | 22.80 |
Materialise NV is a provider of 3D-printed medical devices and software and a pioneer in additive manufacturing software and services. The company operates through three principal segments: Materialise Software, Materialise Medical, and Materialise Manufacturing, with the Materialise Medical segment generating maximum revenue. The Materialise Medical segment develops and delivers medical software solutions, medical devices, and related products and services; the Materialise Software segment develops and delivers additive manufacturing software solutions and related services; and the Materialise Manufacturing segment delivers 3D-printed products and related services. The company generates maximum revenue from the United States of America.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.